View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 20, 2020

Serum Institute of India brings Covid-19 vaccine into animal testing

Serum Institute of India has announced that its new Covid-19 vaccine candidate, being developed in collaboration with US-based Codagenix, is now in pre-clinical / animal testing phase.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.

Serum Institute of India has announced that its new Covid-19 vaccine candidate, being developed in collaboration with US-based Codagenix, is now in pre-clinical / animal testing phase.

Preclinical data from mice and primates should be available by the end of August, with these results submitted to regulatory authorities.

The vaccine candidate is expected to enter human clinical trials in the coming six months and be market-ready by early 2022.

Serum Institute of India estimates the cost of the project to be up to Rs3bn ($41.9m) and plans to form global alliances to obtain funding.

Commenting on the vaccine development progress, Serum Institute of India CEO Adar Poonawalla said: “The combined efforts with the team at Codagenix have borne fruit and we hope to save millions of lives with this vaccine. While several efforts have been made to finding a cure as well as in controlling the outbreak, this is the first vaccine-virus strain to progress to the pre-clinical trial phase.”

Last week, Codagenix and Serum Institute of India partnered to develop a live-attenuated vaccine using Codagenix’s deoptimisation technology.

The vaccine-virus strain developed by the companies is identical to the original virus, expected to be the fastest such India-made vaccine to advance into human trials within six months.

Furthermore, the partners are considering China as a potential site for trials.


See all Coronavirus vaccines and drugs in the pipeline

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena